Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merus N.V. CS (NQ: MRUS ) 56.15 -0.76 (-1.34%) Streaming Delayed Price Updated: 10:47 AM EDT, Jun 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 137,827 Open 57.00 Bid (Size) 56.06 (4) Ask (Size) 56.16 (2) Prev. Close 56.91 Today's Range 55.95 - 57.63 52wk Range 19.80 - 61.61 Shares Outstanding 46,530,884 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting June 03, 2024 From Merus N.V. Via GlobeNewswire Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting June 02, 2024 From Merus N.V. Via GlobeNewswire Performance YTD +96.19% +96.19% 1 Month +2.33% +2.33% 3 Month +25.45% +25.45% 6 Month +95.92% +95.92% 1 Year +122.82% +122.82% More News Read More Merus Announces Pricing of Upsized Public Offering of Common Shares May 29, 2024 From Merus N.V. Via GlobeNewswire Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference May 29, 2024 From Merus N.V. Via GlobeNewswire Merus N.V. Announces Proposed Public Offering of Common Shares May 28, 2024 From Merus N.V. Via GlobeNewswire Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC May 28, 2024 From Merus N.V. Via GlobeNewswire Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 28, 2024 Via Benzinga Crude Oil Rises 1%; Verastem Shares Slide May 24, 2024 Via Benzinga Exposures Fossil Fuels Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session May 24, 2024 Via Benzinga Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday? May 24, 2024 Via Benzinga Nasdaq Gains 1%; Intuit Shares Plunge May 24, 2024 Via Benzinga Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High May 24, 2024 Via Investor's Business Daily Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday May 24, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 24, 2024 Via InvestorPlace Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting May 23, 2024 From Merus N.V. Via GlobeNewswire Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting May 23, 2024 From Merus N.V. Via GlobeNewswire Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA May 13, 2024 From Merus N.V. Via GlobeNewswire MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update May 08, 2024 From Merus N.V. Via GlobeNewswire Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 06, 2024 From Merus N.V. Via GlobeNewswire Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting April 24, 2024 From Merus N.V. Via GlobeNewswire Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 April 08, 2024 From Merus N.V. Via GlobeNewswire Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Merus N.V. Via GlobeNewswire Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers March 06, 2024 From Gilead Sciences, Inc. Via Business Wire Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression March 05, 2024 From Merus N.V. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
